Tern secures £45,000 bridging loan ahead of open offer

Tern Plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that ahead of the expected receipt of funds from the Company’s underwritten open offer to raise approximately £642,486 (before expenses) announced on 14 July 2025, Tern has received a bridging loan, which has been provided by a vehicle controlled by Al Sisto, non-board CEO of Tern, for the amount of approximately £45,000.

The proceeds of the Bridging Loan will be utilised to fulfil a commitment to one of Tern’s investments, and in doing so will allow Tern to retain its rights in relation to this investment, and for general corporate purposes until the expected receipt of funds from the Underwritten Open Offer, which is expected to be on or around 31 July 2025. As at 30 June 2025, the Company’s unaudited cash balance was approximately £70,000.

The Bridging Loan is an unsecured loan that is repayable on 1 August 2025, which is following the expected receipt of funds from the Underwritten Open Offer. The effective annual interest rate on the Bridging Loan is approximately 12%, which equates to approximately £150 during the term of the loan.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Search